United Therapeutics ( UTHR Quick Quote UTHR - Free Report) announced that the FDA has issued a complete response letter to its new drug application (“NDA”) for its drug device combination therapy, Tyvaso Dry Powder Inhaler or Tyvaso DPI.
The NDA is seeking approval for the candidate to treat pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). Tyvaso DPI comprises the dry powder formulation of United Therapeutics’ PAH medicine, Tyvaso (treprostinil), and a small, portable, dry powder inhaler.
Per the complete response letter (“CRL”), the FDA identified a deficiency related to an open inspection issue at a third-party facility that performs analytical testing of treprostinil drug substance. This prevented the FDA from approving the NDA in its present form.
United Therapeutics has developed Tyvaso DPI in collaboration with
MannKind Corporation ( MNKD Quick Quote MNKD - Free Report) . The FDA did not report any deficiencies in its CRL with regard to operations at MannKind's device manufacturing and testing facility for Tyvaso DPI.
Shares of both Mannkind and United Therapeutics were down 18.3% and 1.5%, respectively, in intra-day trading on Oct 18, following the above news. Nonetheless, in the year so far, United Therapeutics’ shares have rallied 21.4% against the
industry’s 16.9% decline. Image Source: Zacks Investment Research
Following the CRL, the company anticipates that the FDA’s query regarding the deficiency can be resolved quickly and it can obtain approval for Tyvaso DPI in the United States by the summer of 2022.
The drug-device product offers some benefits over nebulized Tyvaso Inhalation Solution, which is already approved in the United States for the treatment of PAH and PH-ILD. Tyvaso DPI is expected to be less time-consuming to administer, and more mobile and convenient. The NDA filing was based on data from the BREEZE study.
If approved, United Therapeutics expects Tyvaso DPI to double the number of patients on Tyvaso by 2022.
Please note that United Therapeutics filed the NDA for Tyvaso DPI earlier this year in April with a priority review voucher. The FDA accepted the NDA and granted priority review to the NDA in June 2021.
Please also note that United Therapeutics is a market leader in PAH medicines. Other than Tyvaso, which is an inhaled version of treprostinil, the company markets three other PAH medicines in the United States — Remodulin, an injectable formulation of treprostinil approved for both subcutaneous and intravenous use; Orenitram, an oral version of treprostinil; and Adcirca tablets. United Therapeutics bought exclusive rights to commercialize Adcirca (tadalafil) for PAH in the United States from
Eli Lilly ( LLY Quick Quote LLY - Free Report) in November 2008. Eli Lilly markets tadalafil as Cialis for erectile dysfunction. Adcirca/Cialis lost exclusivity in 2018 and generic versions are available. Zacks Rank & Stock to Consider
United Therapeutics currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is
Xencor ( XNCR Quick Quote XNCR - Free Report) , which carries a Zacks Rank #1 (Strong Buy) at present. You can see . the complete list of today’s Zacks #1 Rank stocks here
Xencor’s earnings per share estimates for 2021 have narrowed from $0.75 to $0.33 in the past 60 days. The same for 2022 has narrowed from $3.14 to $2.92 over the same period.
(We are reissuing this article to correct a mistake. The original article, issued on October 19, 2021, should no longer be relied upon.)